Protagonist Therapeutics (PTGX) Short Interest Ratio & Short Volume

Short interest is the volume of Protagonist Therapeutics shares that have been sold short but have not yet been covered or closed out. As of September 15th, traders have sold 2,800,000 shares of PTGX short. Learn More on Protagonist Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PTGX shares currently have a short interest ratio of 3.0. Learn More on Protagonist Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Protagonist Therapeutics: Walleye Capital LLC, Walleye Trading LLC, Boothbay Fund Management LLC, Citadel Advisors LLC, PEAK6 Investments LLC, JPMorgan Chase & Co., Belvedere Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Protagonist Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 2,800,000 shares, an increase of 1.8% from the previous total of 2,750,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Protagonist Therapeutics: REGENXBIO Inc. (11.01%), OmniAb, Inc. (4.90%), Zymeworks Inc. (13.70%), Aura Biosciences, Inc. (8.97%), KalVista Pharmaceuticals, Inc. (11.80%), Ocular Therapeutix, Inc. (5.53%), Xenon Pharmaceuticals Inc. (4.32%), Zai Lab Limited (3.40%), Avadel Pharmaceuticals plc (3.74%), Pliant Therapeutics, Inc. (10.55%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Canadian Natural Resources Limited ($8.05 billion), T-Mobile US, Inc. ($3.94 billion), Charter Communications, Inc. ($3.77 billion), Occidental Petroleum Co. ($3.27 billion), Tractor Supply ($2.29 billion), Celsius Holdings, Inc. ($2.20 billion), Rivian Automotive, Inc. ($2.10 billion), Moderna, Inc. ($2.08 billion), Royal Caribbean Cruises Ltd. ($1.90 billion), and T. Rowe Price Group, Inc. ($1.90 billion). View all of the most shorted stocks.

Short selling PTGX is an investing strategy that aims to generate trading profit from Protagonist Therapeutics as its price is falling. PTGX shares are trading down $0.44 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Protagonist Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PTGX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTGX, twice per month. The most recent reporting period available is September, 15 2023.